SAN DIEGO--(BUSINESS WIRE)--Alterome Therapeutics, Inc., a biopharmaceutical company pioneering the development of next generation, small molecule targeted therapies for the treatment of cancer, today announced that data from preclinical studies of ALTA3263, the Company’s potential best-in-class KRAS selective inhibitor, will be presented in a plenary oral session at the EORTC-NCI-AACR (ENA) Symposium, taking place on October 23-25 in Barcelona, Spain..

圣地亚哥--（商业新闻短讯）--Alterome Therapeutics，Inc.，一家开创下一代小分子靶向治疗癌症的生物制药公司，今天宣布，该公司潜在的同类最佳KRAS选择性抑制剂ALTA3263的临床前研究数据将在10月23日至25日在西班牙巴塞罗那举行的EORTC-NCI-AACR（ENA）研讨会的全体口头会议上发表。。

“ALTA3263 induces deep and durable tumor regressions in preclinical models addicted to the most common KRAS mutations, G12D, G12V, and G12C,” said Eric Murphy, Ph.D., co-founder and CEO of Alterome Therapeutics. “Mutant KRAS is a driver in approximately 1 out of every 5 cancers and ALTA3263 has the potential to be a robust treatment option for a wide range of KRAS mutant cancers based on its compelling preclinical profile.”.

Alterome Therapeutics联合创始人兼首席执行官埃里克·墨菲（EricMurphy）博士说：“ALTA3263在对最常见的KRAS突变G12D，G12V和G12C上瘾的临床前模型中诱导了深度和持久的肿瘤消退。”。“突变KRAS是每5种癌症中约1种癌症的驱动因素，基于其引人注目的临床前特征，ALTA3263有可能成为多种KRAS突变癌症的强大治疗选择。”。

Key Findings:

主要发现：

ALTA3263 is an oral, KRAS selective inhibitor designed to enable complete target coverage of the most common mutations including G12V and G12D.

ALTA3263是一种口服KRAS选择性抑制剂，旨在实现包括G12V和G12D在内的最常见突变的完全靶向覆盖。

ALTA3263 demonstrates potent KRAS ON-state inhibition, picomolar to low single digit nanomolar potency against cells harboring a diverse array of KRAS driver mutations, and is highly selective for KRAS versus the NRAS and HRAS isoforms.

。

ALTA3263 induced complete and sustained tumor regressions in 8 KRAS G12V/D/C/A mutant xenograft models, including complete responses in 2 patient-derived xenograft non-small cell lung cancer models, while being well-tolerated during prolonged daily oral dosing in mice.

ALTA3263在8个KRAS G12V/D/C/A突变异种移植模型中诱导了完全和持续的肿瘤消退，包括在2个患者来源的异种移植非小细胞肺癌模型中的完全反应，同时在小鼠长时间每日口服给药期间具有良好的耐受性。

Oral Presentation Details:

口头陈述详情：

Title: ALTA3263: an oral, KRAS isoform-selective, dual ON/OFF state, non-covalent inhibitor induces regressions across KRAS G12V, G12D, and G12C cancer models

标题：ALTA3263：口服，KRAS亚型选择性，双开/关状态，非共价抑制剂诱导KRAS G12V，G12D和G12C癌症模型的退化

Session Title: Proffered Papers: New drugs on the Horizon

会议标题：提交的论文：即将出现的新药

Session Type: Plenary Session 6

会议类型：第6次全体会议

Date and Time: Friday, October 25 at 12:36-12:48 p.m. CEST

日期和时间：10月25日星期五下午12:36-12:48 CEST

Speaker/Lead Author: Tim Sen Wang, Ph.D., Alterome Therapeutics

演讲者/主要作者：Tim Sen Wang博士，Alterome Therapeutics

About Alterome Therapeutics, Inc.

关于Alterome Therapeutics，Inc。

Alterome Therapeutics, Inc. is a precision oncology biotech developing alteration-specific therapeutics to address high-value and validated oncogenic drivers. The company is led by an expert team of precision oncology R&D leaders with a history of developing marketed oncology small molecule drugs.

Alterome Therapeutics，Inc.是一家精密肿瘤学生物技术公司，开发改变特异性疗法，以解决高价值和经过验证的致癌驱动因素。该公司由具有开发上市肿瘤小分子药物历史的精准肿瘤研发领导者组成的专家团队领导。

For more information, visit www.alterome.com.

Follow us on LinkedIn and Twitter.

在LinkedIn和Twitter上关注我们。